Adverse Drug Event Clinical Trial
Official title:
How Safe Are Our Pediatric Emergency Departments? A National Prospective Cohort Study
Verified date | January 2018 |
Source | Children's Hospital of Eastern Ontario |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Patient safety is an internationally recognized health care priority. Canadian data suggests that about 8% of adults admitted to hospital experience unintended harm (or 'adverse events') from the health care provided during their hospital stay. On a national level, this represents almost 25,000 preventable deaths among hospitalized adults each year. The emergency department is recognized as a high-risk environment for adverse events but most patient safety research is not specific to the emergency department. As well, the vast majority of people treated in the emergency department are sent home after their visit; yet safety research focuses primarily on people who are admitted to hospital. Finally, although children have also been identified as particularly high risk for suffering adverse events, very little research has been done on how often these events occur among children who visit the emergency department. Our study will address this gap in our knowledge about patient safety and provide important information on the frequency, severity and preventability of adverse events occurring among children in the emergency department. This information will help us to improve the safety of emergency department care for all Canadian children.
Status | Completed |
Enrollment | 6385 |
Est. completion date | March 2017 |
Est. primary completion date | November 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 18 Years |
Eligibility |
Inclusion Criteria: - Age less than 18 years - Patients from all pediatric Canadian Triage Acuity Scale categories (pedsCTAS; 1:resuscitation; 2:emergent, 3:urgent, 4:semi-urgent, 5:non-urgent). Exclusion Criteria: - Insurmountable language barrier that prevents informed consent and follow-up by telephone. - Children and families that will be unavailable for telephone follow-up in the three weeks after their emergency department visit (e.g., no telephone in the home, travelling out of the country, etc.). |
Country | Name | City | State |
---|---|---|---|
Canada | Alberta Children's Hospital | Calgary | Alberta |
Canada | Stollery Children's Hospital | Edmonton | Alberta |
Canada | Children's Hospital at London Health Sciences Centre | London | Ontario |
Canada | CHU Sainte-Justine | Montreal | Quebec |
Canada | Children's Hospital for Eastern Ontario | Ottawa | Ontario |
Canada | Janeway Children's Health and Rehabilitation Centre | St. John | Newfoundland and Labrador |
Canada | The Hospital for Sick Children | Toronto | Ontario |
Canada | BC Children's Hospital | Vancouver | British Columbia |
Canada | Manitoba Institute of Child Health | Winnipeg | Manitoba |
Canada | Winnipeg Children's Hospital | Winnipeg | Manitoba |
Lead Sponsor | Collaborator |
---|---|
Children's Hospital of Eastern Ontario | Alberta Children's Hospital, Janeway Children's Health and Rehabilitation Centre, London Health Sciences Centre, Manitoba Institute of Child Health, Ottawa Hospital Research Institute, Provincial Health Services Authority, St. Justine's Hospital, Stollery Children's Hospital, The Children's Hospital of Winnipeg, The Hospital for Sick Children |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of patients who experience an adverse event related to emergency department care within 3 weeks of an emergency department visit | An adverse event will be defined as an event that results in unintended harm to the patient, and is related to the health care and/or services provided to the patient rather than to the patient's underlying medical condition. Emergency department care will be defined as any care provided in the emergency department and will explicitly include care provided by emergency department specific staff (i.e., staff physicians, nurses, and allied health care providers) and care provided by consultants in the emergency department. | 3 weeks | |
Secondary | Proportion of patients experiencing a preventable adverse event | 3 weeks | ||
Secondary | Clinical severity of adverse events | For all patients, we will report the clinical severity as: (a) an abnormality on laboratory testing, (b) =1 day of symptoms, (c) >1 day of symptoms, (d) nonpermanent disability (e) permanent disability, or (f) death. For admitted patients, we will also report clinical severity according to The Institute for Health Care Improvement trigger tool categories: (a) temporary harm to the patient requiring intervention, (b) temporary harm to the patient requiring initial or prolonged hospitalization, (c) permanent patient harm, (d) intervention required to sustain life, or (e) death. | 3 weeks | |
Secondary | Types of adverse events | Adverse Events will be classified as (a) diagnostic issue, (b) management issue, (c) unsafe disposition decision, (d) suboptimal follow-up, (e) medication adverse effect, (f) procedural complication, and (g) nosocomial infection | 3 weeks | |
Secondary | System response required for adverse events | The response will be classified as: (a) no treatment (symptoms only), (b) required medical/surgical intervention, (c) visit to MD office, (d) Emergency Department visit, (e) admission to hospital. These previously published broad categories were chosen in order to address the effect of the Adverse Events at both the patient and health care system level.These categories are not exclusive. | 3 weeks | |
Secondary | Proportion of patients for whom an adverse event is related to emergency department specific care | Versus consulting specialty service care provided in the emergency department or care provided after the child's emergency department visit | 3 weeks | |
Secondary | Adverse events related to care provided in the emergency department by consulting service | 3 weeks | ||
Secondary | Patient and system level characteristics associated with adverse events and preventable adverse events | 3 weeks | ||
Secondary | Adverse events that occur within the 3-week time frame but are not related to care received in the emergency department | Including those related to in-hospital care and primary care | 3 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03638726 -
Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification
|
Phase 4 | |
Completed |
NCT05007041 -
Simultaneous RZV and aIIV4 Vaccination
|
Phase 4 | |
Suspended |
NCT02559960 -
Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study
|
||
Completed |
NCT05266300 -
Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.
|
||
Completed |
NCT03112083 -
Safety and Tolerability of Krill Powder Supplement in Slightly Overweight People With Moderately Elevated Blood Pressure
|
N/A | |
Completed |
NCT05028361 -
Simultaneous mRNA COVID-19 and IIV4 Vaccination Study
|
Phase 4 | |
Completed |
NCT04284553 -
Optimizing Electronic Health Record Prompts With Behavioral Economics to Improve Prescribing for Older Adults
|
N/A | |
Recruiting |
NCT06120712 -
A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of Advanced Melanoma (MIZAR-002)
|
Phase 1/Phase 2 | |
Completed |
NCT04181775 -
Effectiveness of an ADE-related Hospitalization Risk Prediction Tool for Patients (ADE-RED)
|
||
Completed |
NCT02906657 -
Medication Reconciliation Using Electronic Pharmaceutical Record: A Multicenter Study in the Hospitalized Elderly
|
N/A | |
Completed |
NCT03640273 -
Efficacy and Adverse Effects of Prapchompoothaweep Remedy and Loratadine for Treatment in AR Patients
|
Phase 2 | |
Completed |
NCT01897870 -
The Effect of a Pharmacist Home Visit on Drug-related Problems Post-discharge.
|
N/A | |
Completed |
NCT03725046 -
Impact of an Optimized Communication on the Readmission for Adverse Drug Event
|
N/A | |
Recruiting |
NCT04635956 -
Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas
|
Phase 2 | |
Active, not recruiting |
NCT05538065 -
NUDGE-EHR Replication Trial at Mass General Brigham
|
N/A | |
Completed |
NCT03442010 -
Adverse Drug Events at Emergency Department
|
||
Recruiting |
NCT04791150 -
Rheumatologic Adverse Events and Cancer Immunotherapy
|
N/A | |
Completed |
NCT02864030 -
PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment
|
Phase 4 | |
Completed |
NCT03665402 -
A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status
|
N/A | |
Recruiting |
NCT05799053 -
Peppermint Oil for the Treatment of Irritable Bowel Syndrome or Functional Abdominal Pain in Children: the MINT Study
|
Phase 3 |